Skip to main content
SpringerLink
Log in

Lymphome de Hodgkin : traitement de première ligne des stades avancés

  • Chapter
Actualités thérapeutiques dans les lymphomes

  • 548 Accesses

Résumé

Le paysage de la prise en charge des lymphomes de Hodgkin (LH) avancés s’est sensiblement modifié durant les 10 dernières années. L’introduction de nouveaux schémas thérapeutiques plus intenses permet d’améliorer le contrôle de la maladie, mais la meilleure balance entre efficacité et toxicité des traitements reste à trouver. Par ailleurs, la récente introduction de l’imagerie fonctionnelle dont la sensibilité est meilleure que celle du scanner, a permis d’une part d’identifier plus fréquemment des patients ayant un stade avancé [1], et d’autre part de développer des stratégies thérapeutiques adaptées au risque d’échec du traitement évalué par la sensibilité précoce à la chimiothérapie.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Hutchings M, Loft A, Hansen M, et al. (2006) Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 91(4): 482–9

    PubMed  Google Scholar 

  2. Engert A, Diehl V, Franklin J, et al. (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27(27): 4548–54

    Article  PubMed  Google Scholar 

  3. Borchmann P, Haverkamp H, Diehl V, et al. (2011) Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 29(32): 4234–42

    Article  PubMed  CAS  Google Scholar 

  4. Chisesi T, Bellei M, Luminari S, et al. (2011) Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin’s lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol 29(32): 4227–33

    Article  PubMed  CAS  Google Scholar 

  5. Federico M, Luminari S, Iannitto E, et al. (2009) ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfbmi Trial. J Clin Oncol 27(5): 805–11

    Article  PubMed  Google Scholar 

  6. Viviani S, Zinzani PL, Rambaldi A, et al. (2011) ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 365(3): 203–12

    Article  PubMed  CAS  Google Scholar 

  7. Fermé C, Mounier N, Casasnovas O, et al. (2006) Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d’Étude des Lymphomes de l’Adulte (GELA). Blood 107(12): 4636–42

    Article  PubMed  Google Scholar 

  8. Aleman BMP, Raemaekers JMM, Tirelli U, et al. (2003) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 348(24): 2396–2406

    Article  PubMed  Google Scholar 

  9. Canellos GP, Anderson JR, Propert KJ, et al. (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327(21): 1478–84

    Article  PubMed  CAS  Google Scholar 

  10. Duggan DB, Petroni GR, Johnson JL, et al. (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21(4): 607–14

    Article  PubMed  CAS  Google Scholar 

  11. Glick JH, Young ML, Harrington D, et al. (1998) MOPP/ABV hybrid chemotherapy for advanced Hodgkin’s disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 16(1): 19–26

    PubMed  CAS  Google Scholar 

  12. Diehl V, Franklin J, Pfreundschuh M, et al. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348(24): 2386–95

    Article  PubMed  CAS  Google Scholar 

  13. Carde P, Karrasch M, Fortpied C, et al. (2012) ABVD (8 cycles) vs. BEACOPP (4 escalated cycles ⇒ 4 baseline) in stage III–IV high risk Hodgkin Lymphoma (HL): first results of EORTC Intergroup 20012 study. ASCO 2012

    Google Scholar 

  14. Morschhauser F, Brice P, Fermé C, et al. (2008) Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 26(36): 5980–7

    Article  PubMed  Google Scholar 

  15. Bauer K, Skoetz N, Monsef I, et al. (2011) Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev (8): CD007941

    PubMed  Google Scholar 

  16. 16. Engert A (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomized, open-label, phase 3 non-inferiority trial. Lancet Online 4th April 2012

    Google Scholar 

  17. Gobbi PG, Levis A, Chisesi T, et al. (2005) ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate-and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23(36): 9198–9207

    Article  PubMed  CAS  Google Scholar 

  18. Johnson PWM, Radford JA, Cullen MH, et al. (2005) Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 23(36): 9208–18

    Article  PubMed  CAS  Google Scholar 

  19. Radford JA, Rohatiner AZS, Ryder WDJ, et al. (2002) ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin’s disease. J Clin Oncol 20(13): 2988–94

    Article  PubMed  CAS  Google Scholar 

  20. Steidl C, Telenius A, Shah SP, et al. (2010) Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood 116(3): 418–27

    Article  PubMed  CAS  Google Scholar 

  21. Steidl C, Lee T, Shah SP, et al. (2010) Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 362(10): 875–85

    Article  PubMed  CAS  Google Scholar 

  22. Xie L, Ushmorov A, Leithäuser F, et al. (2012) FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood (doi: 10.1182/blood-2011-09-381905)

    Google Scholar 

  23. Chetaille B, Bertucci F, Finetti P, et al. (2009) Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 113(12): 2765–3775

    Article  PubMed  CAS  Google Scholar 

  24. Sánchez-Espiridión B, Montalbán C, López A, et al. (2010) A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood 116(8): e12–7

    Article  PubMed  Google Scholar 

  25. Casasnovas RO, Mounier N, Brice P, et al. (2007) Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin’s lymphoma: a study from the Groupe d’Étude des Lymphomes de l’Adulte. J Clin Oncol 25(13): 1732–40

    Article  PubMed  CAS  Google Scholar 

  26. Weihrauch MR, Manzke O, Beyer M, et al. (2005) Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin’s disease: potential for a prognostic factor. Cancer Res 65(13): 5516–9

    Article  PubMed  CAS  Google Scholar 

  27. Gallamini A, Patti C, Viviani S, et al. (2011) Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 152(5): 551–60

    Article  PubMed  Google Scholar 

  28. Federico M, Bellei M, Brice P, et al. (2003) High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. J Clin Oncol 21(12): 2320–5

    Article  PubMed  CAS  Google Scholar 

  29. Straus DJ, Gaynor JJ, Myers J, et al. (1990) Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 8(7): 1173–86

    PubMed  CAS  Google Scholar 

  30. Arakelyan N, Berthou C, Desablens B, et al. (2008) Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group. Cancer 113(12): 3323–30

    Article  PubMed  CAS  Google Scholar 

  31. Ng AK, Kenney LB, Gilbert ES, Travis LB (2010) Secondary malignancies across the age spectrum. Semin Radiat Oncol 20(1): 67–78

    Article  PubMed  Google Scholar 

  32. Johnson PW, Sydes MR, Hancock BW, et al. (2010) Consolidation radiotherapy in patients with advanced Hodgkin’s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol 28(20): 3352–9

    Article  PubMed  Google Scholar 

  33. Kobe C, Dietlein M, Franklin J, et al. (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112(10): 3989–94

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. hématologie clinique, hôpital Le Bocage, CHU Dijon, 21079, Dijon, France

    R. O. Casasnovas

Authors
  1. R. O. Casasnovas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. O. Casasnovas .

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Paris

About this chapter

Cite this chapter

Casasnovas, R.O. (2013). Lymphome de Hodgkin : traitement de première ligne des stades avancés. In: Actualités thérapeutiques dans les lymphomes. Springer, Paris. https://doi.org/10.1007/978-2-8178-0371-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0371-5_2

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0370-8

  • Online ISBN: 978-2-8178-0371-5

Publish with us

Policies and ethics

Search

Navigation